Latest Tocagen Inc. Stories
Following Meeting with FDA, Company Advances Towards Pivotal Phase 2/3 Trial in Patients with Recurrent High Grade Glioma WASHINGTON, May 4, 2015 /PRNewswire/ --
SAN DIEGO, April 30, 2015 /PRNewswire/ -- Tocagen Inc., a clinical-stage immuno-oncology company, today announced updated
Industry and Academic Leader Co-Founded Several Successful Biotechnology Companies, Including Alnylam, Cubist and Alkermes SAN DIEGO, Feb.
SAN DIEGO, Dec.
Results Presented at the 19th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology MIAMI, Nov.
Builds Expert Independent Board As Company Advances Towards Late-Stage Brain Cancer Trials SAN DIEGO, Nov.
Names Wayne Saville, M.D., Vice President, Clinical Development, and Mary Rose Keller Vice President, Clinical Operations SAN DIEGO, Aug.
In Addition, Toca 511 Clinical Data to be Presented at American Society of Clinical Oncology Annual Meeting SAN DIEGO, May 22, 2014 /PRNewswire/ --
- The horn of a unicorn considered as a medical or pharmacological ingredient.
- A winged horse with a single horn on its head; a winged unicorn.